Not only did PKCβ inhibition synergize with PARPi in breast cancer cell lines, the combinatorial efficacy was also evidenced for the BRCA wildtype ES2 (Fig. 4c) and BRCA-mutant COV362 ovarian cancer cell lines (Fig. 4d). This evidence concerns the gene PRKCB and ovarian cancer.